MDI Therapeutics is a discovery stage company focused on developing novel therapies for fibrotic diseases. By harnessing the potential of serpin biology, we aim to prevent fibrosis and even reverse the fibrotic disease process. Our scientific approach is to intercept the biological processes of the fibrin fibrotic matrix, the common denominator of all fibrotic disorders. We have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments using clinical biomarkers. We have assembled a management team with a combination of drug development and world-renown basic research expertise in serpin biology. MDI Therapeutics is therefore positioned to be the global leader in developing novel therapeutics for fibrotic diseases by targeting this critical protein family. serpin